Simvastatin improves spinal fusion in rats

Acta Orthop Traumatol Turc. 2011;45(4):270-5. doi: 10.3944/AOTT.2011.2526.

Abstract

Objective: Statins stimulate bone formation by inducing the expression of bone morphogenetic proteins (BMP-2). The aim of our study was to investigate the effects of orally administered simvastatin on spinal fusion in rats.

Methods: Twenty rats were randomized into a spinal fusion group (SF) (n=10) or a spinal fusion and oral simvastatin administered group (SFS) (n=10). A spinal fusion was performed between L4-L6 representing two levels. Simvastatin (120 mg/kg/day) was administered orally in the SFS group. The rats were killed at the end of the 12 week study period.

Results: Manual palpation revealed two moderate fusions in the SF group. The SFS group did not reveal any signs of pseudoarthrosis. An average three-point bending force causing failure of fusion revealed results of 148.80±39.403 Newtons and 123.80±28.479 Newtons in SFS and SF groups, respectively (p>0.05). Histological examination revealed better fusion grades in the SFS group (mean: 9.30±0.949) than in the SF group (mean: 6.80±2.044) (p=0.003). Radiographic examination revealed Grade C fusion in two levels and Grade A fusion in 18 levels in the SF group. In the SFS group, Grade C fusion was detected in one level and Grade A fusions in 19.

Conclusion: Our results suggest that simvastatin can promote spinal fusion and can be used as an adjunct to spinal fusion procedures in an elderly population with high cholesterol levels.

MeSH terms

  • Administration, Oral
  • Animals
  • Bone Morphogenetic Protein 2 / metabolism
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology*
  • Lumbar Vertebrae / metabolism*
  • Lumbar Vertebrae / surgery*
  • Male
  • Osteogenesis / drug effects
  • Pseudarthrosis / prevention & control
  • Rats
  • Rats, Sprague-Dawley
  • Simvastatin / administration & dosage
  • Simvastatin / pharmacology*
  • Spinal Fusion / methods*

Substances

  • BMP2 protein, human
  • Bone Morphogenetic Protein 2
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Simvastatin